ALNY Stock Overview
A biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community Narratives
Narratives bring a range of perspectives from our community.
Vutrisiran Poised To Transform Cardiomyopathy Treatment And Skyrocket Revenue Growth
Alnylam Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$261.73 |
| 52 Week High | US$287.55 |
| 52 Week Low | US$141.98 |
| Beta | 0.38 |
| 11 Month Change | -2.20% |
| 3 Month Change | 63.18% |
| 1 Year Change | 35.57% |
| 33 Year Change | 37.61% |
| 5 Year Change | 209.37% |
| Change since IPO | 4,254.91% |
Recent News & Updates
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?
Sep 12
Alnylam: HELIOS-B Success Priced In Already
Aug 30Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results
Aug 04Recent updates
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?
Sep 12Alnylam: HELIOS-B Success Priced In Already
Aug 30Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results
Aug 04Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher
Aug 02RNAi: Winning In The Clinic, Now For The Market
Jun 25Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
Jun 03Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking
Mar 19Is Alnylam's HELIOS-B Delay A Red Flag?
Mar 10Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think
Feb 18Alnylam's Huge Opportunity
Jan 12Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues
Dec 18Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares
Jun 23Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?
Oct 25Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo
Oct 07Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market
Sep 26Alnylam RNAi therapy for rare protein disorder gets EU approval
Sep 20Alnylam to offer $900M convertible senior notes
Sep 12Shareholder Returns
| ALNY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.1% | 2.3% | 1.6% |
| 1Y | 35.6% | 15.9% | 22.0% |
Return vs Industry: ALNY exceeded the US Biotechs industry which returned 16.5% over the past year.
Return vs Market: ALNY exceeded the US Market which returned 21.7% over the past year.
Price Volatility
| ALNY volatility | |
|---|---|
| ALNY Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALNY's share price has been volatile over the past 3 months.
Volatility Over Time: ALNY's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 2,100 | Yvonne Greenstreet | www.alnylam.com |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.
Alnylam Pharmaceuticals, Inc. Fundamentals Summary
| ALNY fundamental statistics | |
|---|---|
| Market cap | US$33.62b |
| Earnings (TTM) | -US$72.94m |
| Revenue (TTM) | US$2.34b |
14.3x
P/S Ratio-460.7x
P/E RatioIs ALNY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALNY income statement (TTM) | |
|---|---|
| Revenue | US$2.34b |
| Cost of Revenue | US$304.82m |
| Gross Profit | US$2.04b |
| Other Expenses | US$2.11b |
| Earnings | -US$72.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 87.00% |
| Net Profit Margin | -3.11% |
| Debt/Equity Ratio | -79,140.2% |
How did ALNY perform over the long term?
See historical performance and comparison